Personal tools
You are here: Home Knowledge Base Psychiatric Drug Industry US Congress Investigates Psychiatric Drug Industry
Look inside...
 

US Congress Investigates Psychiatric Drug Industry

Several different USA Congressional committees have been asked to investigate corruption, fraud and cover-up by the psychiatric drug industry.

Article Top Psychiatrist Didn't Report Drug Makers' Pay
NY Times continues coverage of congressional investigation led by Senator Charles E. Grassley (R-IA) exposing psychiatric drug company corruption, this time involving Dr. Charles B. Nemeroff of Emory University, who has resigned as chair of his department.
Article "Psychiatric Group Faces Scrutiny Over Industry Ties"
In this article, The New York Times covers the demand by Senator Charles E. Grassley (R-IA) that the APA become more transparent in its financing after numerous conflicts of interest were revealed.
Folder Sunday New York Times on Congressional investigation of Harvard psychiatrist
US Senator Charles E. Grassley helped investigate corruption by the psychiatric drug industry. His investigation revealed that Harvard psychiatrist Dr. Joseph Biederman had illegally covered up much of more than a million dollars he had received from the psychiatric drug industry. Dr. Biederman is credited with helping to increase the number of young people diagnosed as "bipolar" many-fold.
Article House Lawmaker Seeks Data From Makers of Stents and Drugs
Congressman Henry Waxman (D-Calif.) is looking into allegations of inappropriate marketing of Zyprexa and other drugs and medical devices, according to Reuters. Waxman is the chairman of a house committee investigating off-label drug marketing by Eli Lilly & Company, AstraZeneca and Cephalon. Off-label use occurs when doctors prescribe products for unapproved purposes.
Article Research Center Tied to Drug Company
Further reports from The New York Times about how a Congressional investigation revealed that psychiatrist Dr. Joseph Biederman misused the name of his institution -- Harvard -- to fraudulently promote the massive use of the psychiatric drgus known as neuroleptics or antipsychotics.
Article Expert or Shill?
The New York Times editorial board weighs in on the corruption in the psychiatric industry exposed by recent USA Congressional investigations.
Article No Mugs, but What About Those Fees
The Sunday New York Times editorialized that the corruption exposed between the psychiatric profession and the drug industry must end.
Document Actions
Donate Now

Give securely online and indicate if you have a preferred campaign that you'd like to support with your donation!

We are MFI



Peter Lehmann, editor, author, psychiatric survivor activist

Peter Lehmann of Berlin, Germany serves as one of the MindFreedom International representatives with the United Nations, and is a long-term supporter of MindFreedom campaigns and activities. Peter is a psychiatric survivor who has worked passionately for decades in Germany, Europe and internationally with a variety of groups for significant change in the mental health system. Peter is editor and publisher of a variety of books challenging human rights violations in the mental health system and promoting alternatives. His most recent book (co-edited with Peter Stastny, MD) is called "Alternatives Beyond Psychiatry." This book provides chapters from 61 leaders in changing the mental health system, and is available in the MindFreedom Mad Market.
Sign Up Today!





Social and Email Marketing by VerticalResponse
Facebook Like Box